We are live on ! Find out more

SeaStar Medical

ICU

Market cap $4.46M

0.8384 USD

-0.2116

20.15%

At close Updated Nov 13, 4:00 PM EST

Pre-market

After hours

0.8100

-0.0284

3.39%

1 day

-20.15%

5 days

-56.33%

1 month

-76.65%

3 months

-73.55%

6 months

-81.77%

Year to date

-68.12%

1 year

-81.77%

5 years

-99.97%

10 years

-99.97%

About: SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Employees: 17

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

SeaStar Medical Holding Corporation (ICU) Q3 2026 Earnings Call Transcript

SeaStar Medical Holding Corporation (ICU) Q3 2026 Earnings Call Transcript

SeaStar Medical Holding Corporation (ICU) Q3 2026 Earnings Call Transcript

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Wednesday, November 11, 2026, and host a webcast and conference call to discuss its financial results and business progress.

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry (SAVE Registry) has fulfilled the post-approval study requirements as outlined in the original Humanitarian Device Exemption (HDE) approval of QUELIMMUNE.

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort No device-related adverse events (AEs) occurred in patients treated with QUELIMMUNE DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today new positive data from the late-breaking presentation at ASN Kidney Week 2026 in Denver, Colorado. The late-breaking poster, titled “Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort,” compared survival in QUELIMMUNE (SCD-PED)-treated critically ill pediatric patients from its post-approval SAVE registry and one non-registry patient with life-threatening acute kidney injury (AKI) and sepsis requiring CRRT (QUELIMMUNE SCD-PED cohort) with clinically aligned cohorts from Kids' Inpatient Database (KID), the largest publicly available, all-payer pediatric inpatient care database in the United States representing broad clinical complexity.

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

Award recognizes Dr. Chung's extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. The Breakthrough Device Designation is a regulatory pathway designed to provide for accelerated development, assessment, and review for FDA approval of medical devices and potentially more effective treatments of life-threatening or irreversibly debilitating diseases or conditions.

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical's common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the “Prior Warrants”), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of $3.866 per share, for aggregate gross proceeds of approximately $3.3 million, before deducting placement agent fees and other offering expenses. The shares of common stock issuable upon the exercise of the Prior Warrants are registered pursuant to effective registration statements on Form S-1 (Nos.

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI)

New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced that effective today, October 1, 2026, new ICD-10-PCS codes are available to enable administrative, billing, and statistical reporting for the use of SeaStar Medical's SCD therapy in patients with AKI requiring renal replacement therapy (RRT) in the inpatient hospital setting. "Availability of these unique ICD-10-PCS codes represents a significant milestone for our company and the clinical community," stated Tim Varacek, Senior Vice President of Commercial and Business Operations of SeaStar Medical.

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI)

See News Rankings

Price charts implemented using Lightweight Charts™